# The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

> **NCT01707992** · PHASE3 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 2199 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Laquinimod
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01707992
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-20
- **Primary completion:** 2015-04-13
- **Final completion:** 2017-07-04
- **Target enrollment:** 2199 (ACTUAL)
- **Last updated:** 2021-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01707992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01707992, "The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01707992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*